Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer-time for a rethink?

about

Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer-time for a rethink?

Item

http://www.wikidata.org/entity/Q52647565

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Reporting and ideal testostero ...... ate cancer-time for a rethink?

@en

Reporting and ideal testostero ...... ate cancer-time for a rethink?

@nl

type

Item

label

Reporting and ideal testostero ...... ate cancer-time for a rethink?

@en

Reporting and ideal testostero ...... ate cancer-time for a rethink?

@nl

prefLabel

Reporting and ideal testostero ...... ate cancer-time for a rethink?

@en

Reporting and ideal testostero ...... ate cancer-time for a rethink?

@nl

P1476

Reporting and ideal testostero ...... ate cancer-time for a rethink?

@en

P2093

Damien M Bolton

http://www.w3.org/2001/XMLSchema#string

Jonathan S O'Brien

http://www.w3.org/2001/XMLSchema#string

Ken Sikaris

http://www.w3.org/2001/XMLSchema#string

Nathan Lawrentschuk

http://www.w3.org/2001/XMLSchema#string

Sonja Cabarkapa

http://www.w3.org/2001/XMLSchema#string

P2860

The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK

Maximal testosterone suppression in prostate cancer--free vs total testosterone

Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT

Evolving issues in male hypogonadism: evaluation, management, and related comorbidities.

Defining a new testosterone threshold for medical castration: Results from a prospective cohort series.

Impact of surgical and medical castration on serum testosterone level in prostate cancer patients.

Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Adverse effects of androgen-deprivation therapy in prostate cancer and their management.

Castration-resistant prostate cancer: AUA guideline amendment.

P304

1-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PRNIL.2017.05.003

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marlon L Perera

P577

2017-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29556482

http://www.w3.org/2001/XMLSchema#string

P932

5857188

http://www.w3.org/2001/XMLSchema#string